Advancing Structured Benefit-Risk Assessment in FDA Review
The Duke-Margolis Center for Health Policy • Washington, DC
October 4, 2017

Participant List

Steven Anderson
Director, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Meghana Chalasani
Operations Research Analyst, Decision Support and Analysis Team, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Victor Crentsil
Associate Director for Regulatory Science, Office of Drug Evaluation III, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Gerald Dal Pan
Director, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Alex Davis
Assistant Professor, Department of Engineering and Public Policy, Carnegie Mellon University

Sara Eggers
Decision Support and Analysis Team, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Baruch Fischhoff
Howard Heinz University Professor, Department of Engineering and Public Policy, Institute for Politics and Strategy, Carnegie Mellon University

Richard Forshee
Associate Director for Research, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Meredith Freed
Senior Research Assistant, Duke-Margolis Center for Health Policy, Duke University

C. Bernie Good
Chair, Medical Advisory Panel, Pharmacy Benefits Management, Department of Veterans Affairs, and Professor, Medicine and Pharmacy, University of Pittsburgh

George Gray
Professor and Interim Chair, Department of Environmental and Occupational Health, Milken Institute of Public Health, George Washington University
Tarek Hammad
Head of Signal Detection and Benefit Risk Assessment, Global Drug Safety Innovation, EMD Serono, Inc.

Brett Hauber
Senior Economist and Vice President, Health Preference Assessment, RTI Health Solutions

Weili He
Head of Global Medical Affairs Statistics, AbbVie

Telba Irony
Deputy Director, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Laura Lee Johnson
Director (Acting), Division of Biometrics III, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Reza Kazemi
Operations Research Analyst, Performance Analysis and Data Services Staff, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Anne Khademian
Director and Professor, School of Public and International Affairs, Virginia Tech

Andrew Kish
Director, Office of Program and Strategic Analysis, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Lisa LaVange
Director, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Kerry Jo Lee
Medical Officer, Guidance and Policy Team, Immediate Office, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Bennett Levitan
Senior Director, Benefit-risk Assessment, Department of Epidemiology, Janssen Research & Development

Megan Moncur
Senior Advisor, Science of Patient Input, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Theresa Mullin
Director, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Rebecca Noel
Global Benefit-Risk Leader, Global Patient Safety, Eli Lilly and Company

Thomas Permutt
Director, Division of Biometrics II, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Lawrence Phillips
Emeritus Professor of Decision Sciences, London School of Economics and Political Science
Claudia Prada
Senior Medical Director, Biogen

Elizabeth Richardson
Managing Associate, Duke-Margolis Center for Health Policy, Duke University

Frank Rockhold
Professor of Biostatistics and Bioinformatics, Duke Clinical Research Institute, Duke University Medical Center

James Smith
Deputy Director, Division of Metabolism and Endocrinology Products, Office of Drug Evaluation II, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Steve Snapinn
Vice President, Global Biostatistical Science, Amgen

Peter Stein
Deputy Director, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Graham Thompson
Operations Research Analyst, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Robert Temple
Deputy Center Director for Clinical Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Ellis Unger
Director, Office of New Drugs, Office of Drug Evaluation I, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Pujita Vaidya
Director (Acting), Decision Support and Analysis Team, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Celia Witten
Deputy Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Shanon Woodward
Operations Research Analyst, Decision Support and Analysis Team, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Hong Yang
Biologist, Analytics and Benefit Risk Assessment Team, Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research, U.S. Food and Drug Administration